ATE248583T1 - In dosierinhalatoren verwendbare, stabilisierte zubereitungen - Google Patents

In dosierinhalatoren verwendbare, stabilisierte zubereitungen

Info

Publication number
ATE248583T1
ATE248583T1 AT98950826T AT98950826T ATE248583T1 AT E248583 T1 ATE248583 T1 AT E248583T1 AT 98950826 T AT98950826 T AT 98950826T AT 98950826 T AT98950826 T AT 98950826T AT E248583 T1 ATE248583 T1 AT E248583T1
Authority
AT
Austria
Prior art keywords
dispersions
patient
stabilized
suspension medium
stabilized preparations
Prior art date
Application number
AT98950826T
Other languages
English (en)
Inventor
Jeffry G Weers
Thomas E Tarara
Luis A Dellamary
Alexey Kabalnov
Ernest G Schutt
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27369827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE248583(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Application granted granted Critical
Publication of ATE248583T1 publication Critical patent/ATE248583T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Optics & Photonics (AREA)
AT98950826T 1997-09-29 1998-09-29 In dosierinhalatoren verwendbare, stabilisierte zubereitungen ATE248583T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6033797P 1997-09-29 1997-09-29
US10693298A 1998-06-29 1998-06-29
US13384898A 1998-08-14 1998-08-14
PCT/US1998/020615 WO1999016422A1 (en) 1997-09-29 1998-09-29 Stabilized preparations for use in metered dose inhalers

Publications (1)

Publication Number Publication Date
ATE248583T1 true ATE248583T1 (de) 2003-09-15

Family

ID=27369827

Family Applications (3)

Application Number Title Priority Date Filing Date
AT98954933T ATE239447T1 (de) 1997-09-29 1998-09-29 In verneblern verwendbare, stabilisierte zubereitungen
AT98950826T ATE248583T1 (de) 1997-09-29 1998-09-29 In dosierinhalatoren verwendbare, stabilisierte zubereitungen
AT98953220T ATE238035T1 (de) 1997-09-29 1998-09-29 Perforierte mikropartikel und deren verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT98954933T ATE239447T1 (de) 1997-09-29 1998-09-29 In verneblern verwendbare, stabilisierte zubereitungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT98953220T ATE238035T1 (de) 1997-09-29 1998-09-29 Perforierte mikropartikel und deren verwendung

Country Status (28)

Country Link
EP (4) EP1019022B2 (de)
JP (9) JP2001517692A (de)
KR (4) KR100589926B1 (de)
CN (1) CN1169520C (de)
AT (3) ATE239447T1 (de)
AU (4) AU757337C (de)
BG (1) BG64816B1 (de)
BR (1) BR9812693A (de)
CA (4) CA2304820C (de)
CZ (1) CZ300758B6 (de)
DE (2) DE69814428T2 (de)
DK (2) DK1019022T4 (de)
EA (2) EA003665B1 (de)
EE (1) EE04628B1 (de)
ES (3) ES2205560T5 (de)
HK (1) HK1031680A1 (de)
HR (1) HRP20000175B1 (de)
IL (2) IL135126A0 (de)
IS (1) IS2154B (de)
ME (1) MEP4108A (de)
NO (1) NO340149B1 (de)
NZ (1) NZ503464A (de)
PL (1) PL195212B1 (de)
PT (1) PT1019022E (de)
RS (1) RS50182B (de)
SK (1) SK285068B6 (de)
TR (1) TR200000819T2 (de)
WO (3) WO1999016419A1 (de)

Families Citing this family (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
DE69814428T2 (de) * 1997-09-29 2004-05-13 Nektar Therapeutics, San Carlos In verneblern verwendbare, stabilisierte zubereitungen
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
GB9727102D0 (en) * 1997-12-22 1998-02-25 Andaris Ltd Microparticles and their therapeutic use
WO2000000215A1 (en) * 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
JP2003535017A (ja) * 1998-06-29 2003-11-25 ネクター セラピューティクス 微粒子デリバリーシステムおよび使用の方法
US6630169B1 (en) 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
US6223455B1 (en) * 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
KR100752000B1 (ko) * 1999-05-27 2007-08-28 아쿠스피어 인코포레이티드. 다공성 약물 매트릭스의 제조방법
JP4874483B2 (ja) 1999-06-09 2012-02-15 ロバート イー． シーバース 超臨界流体補助ネブライゼーション及びバブル乾燥
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
WO2001013891A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US6761909B1 (en) 1999-12-21 2004-07-13 Rxkinetix, Inc. Particulate insulin-containing products and method of manufacture
AU2729101A (en) 1999-12-21 2001-07-03 Rxkinetix, Inc. Particulate drug-containing products and method of manufacture
GB0003935D0 (en) * 2000-02-08 2000-04-12 King S College London Formulation for dry powder inhaler
AU4905701A (en) 2000-02-08 2001-08-20 3M Innovative Properties Company Ink fixing materials and methods of fixing ink
DE60113388T2 (de) 2000-02-08 2006-06-14 3M Innovative Properties Co Verbesserte verfahren für kalten bildtransfer
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
MXPA02001323A (es) * 2000-05-10 2004-07-16 Alliance Pharma Microgranulos con base fosfolipida para la liberacion de farmaco.
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU2001254995A1 (en) * 2000-05-15 2001-11-26 Vectura Limited Method of manufacturing particles
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US7141236B2 (en) 2000-07-28 2006-11-28 Nektar Therapeutics Methods and compositions for delivering macromolecules to or via the respiratory tract
DE10064219B9 (de) * 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US20030072717A1 (en) 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
GB0106403D0 (en) * 2001-03-15 2001-05-02 Pharmaceutical Profiles Labelling of dry powder formulations for inhalation
GB0107106D0 (en) * 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
EP1390012A4 (de) * 2001-04-26 2009-10-28 Novartis Ag Neue verfahren und zusammensetzungen zur freisetzung von makromolekülen an die oder über die atemwege
US7905230B2 (en) 2001-05-09 2011-03-15 Novartis Ag Metered dose inhaler with lockout
DK1389137T3 (da) * 2001-05-21 2006-10-30 Injet Digital Aerosols Ltd Sammensætninger til lungelægemiddellevering af protein
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
DE60230035D1 (de) 2001-05-24 2009-01-08 Alexza Pharmaceuticals Inc Verabreichung von alprazolam, estazolam, midazolam oder triazolam durch inhalation
WO2002094242A1 (en) 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of rizatriptan or zolmitriptan through an inhalation route
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
WO2003000326A1 (en) 2001-06-20 2003-01-03 Nektar Therapeutics Powder aerosolization apparatus and method
JP2005507881A (ja) 2001-09-17 2005-03-24 グラクソ　グループ　リミテッド 乾燥粉末医薬製剤
EP1992335A1 (de) 2001-11-01 2008-11-19 Nektar Therapeutics Sprühtrocknungsverfahren und Zusammensetzungen dafür
WO2003041693A1 (en) 2001-11-09 2003-05-22 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
AU2002363947A1 (en) 2001-11-21 2003-07-24 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
AU2002351271A1 (en) 2001-12-21 2003-07-24 Nektar Therapeutics Capsule package with moisture barrier
EP1486204A1 (de) * 2002-03-18 2004-12-15 Yamanouchi Pharmaceutical Co. Ltd. Pulverförmige medizinische zusammensetzungen zur inhalation und verfahren zu ihrer herstellung
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US6941980B2 (en) 2002-06-27 2005-09-13 Nektar Therapeutics Apparatus and method for filling a receptacle with powder
PA8578501A1 (es) 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
CA2500065A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US7516741B2 (en) 2002-12-06 2009-04-14 Novartis Ag Aerosolization apparatus with feedback mechanism
WO2004054556A1 (en) * 2002-12-13 2004-07-01 Adagit Pharmaceutical porous particles
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7669596B2 (en) 2002-12-31 2010-03-02 Novartis Pharma Ag Aerosolization apparatus with rotating capsule
EP1589947B2 (de) * 2002-12-31 2019-01-30 Novartis AG Pharmazeutische formulierung enthaltend einen unlöslichen wirkstoff zur pulmonalen verabreichung
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
AU2004216298B2 (en) * 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
CN1758930B (zh) 2003-03-27 2010-06-09 株式会社新日本科学 鼻腔用粉末药剂喷药装置
DK1615689T3 (da) 2003-04-09 2016-03-14 Novartis Ag Apparatur til dannelse af en aerosol og omfattende en opretningsføring til punktering af en kapsel
MXPA05010842A (es) 2003-04-09 2006-03-30 Nektar Therapeutics Aparato de nebulizacion con protector de entrada de aire.
US8869794B1 (en) 2003-04-09 2014-10-28 Novartis Pharma Ag Aerosolization apparatus with capsule puncturing member
ATE510174T1 (de) 2003-05-21 2011-06-15 Alexza Pharmaceuticals Inc Schlag gezündete unabhängige heizeinheit
MXPA05012821A (es) 2003-05-28 2006-02-13 Nektar Therapeutics Formulacion farmaceutica que comprende un agente activo insoluble en agua.
JP2007533634A (ja) * 2003-09-30 2007-11-22 アキュスフィア， インコーポレイテッド 注射、経口、または局所用の徐放性医薬製剤
US7621299B2 (en) 2003-10-03 2009-11-24 Cabot Corporation Method and apparatus for filling a vessel with particulate matter
JP2007509989A (ja) * 2003-10-31 2007-04-19 ポイント バイオメディカル コーポレイション 超音波造影剤として有用な再構成可能なミクロスフィア組成物
EP1701714A2 (de) 2004-01-07 2006-09-20 Nektar Therapeutics Verbesserte zusammensetzungen mit verzögerter freisetzung für die pulmonale verabreichung von insulin
WO2005099669A1 (en) * 2004-04-13 2005-10-27 Cambridge Biostability Limited Liquids containing suspended glass particles
ITMI20040795A1 (it) * 2004-04-23 2004-07-23 Eratech S R L Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
EP1773301A2 (de) 2004-06-21 2007-04-18 Nektar Therapeutics Zusammensetzungen mit amphotericinb, verfahren und systeme
US8513204B2 (en) 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
EP1785145A4 (de) 2004-08-10 2008-08-13 Translational Res Ltd Transnasale zusammensetzung mit sofortiger wirkung und hoher resorbierbarkeit
BRPI0513846A (pt) 2004-08-13 2008-05-20 Boehringer Ingelheim Int formulação de comprimido de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e o uso do mesmo
CA2576386A1 (en) 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
BRPI0609700A2 (pt) * 2005-03-23 2010-04-20 Elan Pharma Int Ltd formulações de corticosteróide nanoparticulado e antihistamina
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
WO2006124446A2 (en) * 2005-05-12 2006-11-23 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
JP5087539B2 (ja) 2005-05-18 2012-12-05 ネクター セラピューティックス 気管支内治療のためのバルブ、デバイス、および方法
PE20110071A1 (es) 2005-05-19 2011-01-31 Centocor Inc Anticuerpos anti-mcp-1, composiciones y metodos
HUE042561T2 (hu) 2005-06-30 2019-07-29 Janssen Biotech Inc Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
JP5113328B2 (ja) * 2005-11-07 2013-01-09 田辺三菱製薬株式会社 エマルション並びにそれを用いた目的物質粒子の製造方法及び医薬品
EP2364735A3 (de) 2005-12-16 2012-04-11 Nektar Therapeutics Verzweigte PEG-Kon jugate von GLP-1
ES2517420T3 (es) 2005-12-29 2014-11-03 Janssen Biotech, Inc. Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
EP1976486A1 (de) * 2006-01-27 2008-10-08 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Verfahren zur herstellung von porösen mikroteilchen
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
EP2116264B1 (de) * 2006-12-26 2017-09-27 Shin Nippon Biomedical Laboratories, Ltd. Zubereitung zur transnasalen anwendung
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
WO2009023803A2 (en) * 2007-08-15 2009-02-19 Abbott Respiratory Llc Modulated release formulation for the delivery of one or more medicaments
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2009120619A2 (en) * 2008-03-24 2009-10-01 Novartis Ag Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
PL220269B1 (pl) 2008-04-21 2015-09-30 Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna Kompozytowy nośnik leków proszkowych, sposób wytwarzania nośnika leków oraz urządzenie do wytwarzania cząstek nośnika kompozytowego
BRPI0913021A2 (pt) 2008-05-15 2015-10-13 Novartis Ag distribuição pulmonar de uma fluoroquinolona
WO2010033207A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of therapeutic peptides
AU2009308935B2 (en) 2008-10-31 2015-02-26 Janssen Biotech, Inc. Fibronectin type III domain based scaffold compositions, methods and uses
EP2362766A2 (de) * 2008-11-04 2011-09-07 Cipla Limited Pharmazeutische aerosol-zusammensetzung
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN102596992B (zh) 2009-02-12 2015-09-09 詹森生物科技公司 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
EP2221048A1 (de) 2009-02-18 2010-08-25 Siegfried Generics International AG Pharmazeutische Zusammensetzungen zur Inhalation
EP3552603A1 (de) 2009-03-18 2019-10-16 Incarda Therapeutics, Inc. Einheitsdosen, aerosole, kits und verfahren zur behandlung von herzleiden mittels pulmonaler verabreichung
PT2410981T (pt) 2009-03-26 2017-05-25 Pulmatrix Inc Formulações em pó seco e métodos para tratar doenças pulmonares
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
KR20100123240A (ko) * 2009-05-15 2010-11-24 포항공과대학교 산학협력단 호흡기 염증성 질환의 치료 또는 예방을 위한 호흡기내 투여용 약학 제제 및 상기 질환의 치료 또는 예방 방법
WO2010131486A1 (en) 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
LT2435025T (lt) 2009-05-29 2016-09-26 Pearl Therapeutics, Inc. Veikliosios medžiagos tiekimas per kvėpavimo takus
WO2011013003A2 (en) 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
HUE035862T2 (en) 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid development and / or completion of substantially steady-state drug delivery
CN102811715A (zh) * 2009-12-08 2012-12-05 悉尼大学 可吸入制剂
CN105640925B (zh) 2010-08-30 2019-08-16 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
EP2448571B1 (de) 2010-08-30 2013-06-12 Pulmatrix, Inc. Einatembares trockenpulver mit calciumlactat, natriumchlorid und leukin
AU2011308865B2 (en) 2010-09-29 2017-01-05 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
EP2621488B1 (de) 2010-09-29 2018-11-07 Pulmatrix Operating Company, Inc. Kationische trockenpulver
CA2816119C (en) 2010-10-29 2019-03-05 Western University Of Health Sciences Ternary mixture formulations
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JP2014510064A (ja) * 2011-02-25 2014-04-24 ザ ジョンズ ホプキンス ユニバーシティ Ｎｒｆ２活性剤としてのカルコン誘導体
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
EA201490991A1 (ru) * 2011-05-17 2014-09-30 Перл Терапьютикс, Инк. Композиции, способы и устройства для респираторной доставки двух или более активных средств
GB201117621D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
EP2601941A1 (de) 2011-12-06 2013-06-12 Ludwig-Maximilians-Universität München Verbindungen auf beta-O/S/N-Fettsäurebasis als Antibakterium- und Antiprotozoenmittel
KR20140147891A (ko) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
CN109846862A (zh) 2012-10-25 2019-06-07 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
GB201306984D0 (en) * 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
EP3607941A1 (de) 2013-04-30 2020-02-12 Otitopic Inc. Trockenpulverformulierungen und verfahren zur verwendung
KR101543507B1 (ko) * 2013-05-15 2015-08-11 씨제이헬스케어 주식회사 연속 공정의 미립구의 제조 방법 및 이로부터 제조된 미립구
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
US9861608B2 (en) * 2013-05-23 2018-01-09 Aztherapies, Inc Methods for delivering cromolyn
WO2014207213A1 (en) 2013-06-28 2014-12-31 Medizinische Universität Innsbruck Novel inhibitors of protein kinase c epsilon signaling
US10188757B2 (en) 2013-10-22 2019-01-29 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
HUE047319T2 (hu) 2014-02-10 2020-04-28 Respivant Sciences Gmbh Hízósejt-stabilizátorral történõ kezelés szisztémás rendellenességekhez
US20160367520A1 (en) 2014-02-10 2016-12-22 Patara Pharma, LLC Mast cell stabilizers for lung disease treatment
PL3107548T3 (pl) 2014-02-20 2022-10-31 Otitopic Inc. Suche formulacje w proszku do inhalacji
EP2947460A1 (de) 2014-05-22 2015-11-25 Medizinische Universität Wien Personalisierte Therapie von Entzündungen um Zusammenhang mit Krebs mithilfe von Verfahren zur Bestimmung der Empfänglichkeit auf die Behandlung mit EGFR-Hemmern/-Antagonisten
KR102666667B1 (ko) 2014-07-31 2024-05-17 벡추라 인코포레이티드 흡입용 건조 분말 제형
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016067252A1 (en) 2014-10-31 2016-05-06 Glaxosmithkline Intellectual Property Development Limited Powder formulation
JP6395216B2 (ja) * 2014-11-13 2018-09-26 国立大学法人大阪大学 液体に含まれる超微細バブルの測定方法及びその測定装置
WO2016118625A1 (en) 2015-01-20 2016-07-28 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
US10864190B2 (en) 2015-04-22 2020-12-15 CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH Combination of an antiandrogen with a vitamin K antagonist or with a gamma-glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
CA3007050C (en) 2015-12-04 2020-12-08 Mexichem Fluor S.A. De C.V. Pharmaceutical composition comprising a formoterol compound
PL3386997T3 (pl) 2015-12-09 2021-12-13 Medizinische Universität Wien Funkcjonalizowane monomaleimidem związki platyny do terapii nowotworowej
CN109071482A (zh) 2016-01-15 2018-12-21 汉堡大学 携有o-鼠李糖基残基的类黄酮型化合物
EP3411030A4 (de) 2016-02-01 2019-09-04 InCarda Therapeutics, Inc. Elektronische überwachung mit inhalierter pharmakologischer therapie für das management von herzarrhythmien mit vorhofflimmern
WO2017140728A1 (en) 2016-02-15 2017-08-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Taf1 inhibitors for the therapy of cancer
US10765724B2 (en) 2016-03-29 2020-09-08 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody
US20190111069A1 (en) 2016-04-15 2019-04-18 Oxford University Innovation Limited Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
BR112019000683A2 (pt) 2016-07-15 2019-04-24 Poseida Therapeutics Inc receptores de antígeno quiméricos e métodos para uso
JP2019528044A (ja) 2016-07-15 2019-10-10 ポセイダ セラピューティクス， インコーポレイテッド Ｍｕｃ１に特異的なキメラ抗原受容体（ｃａｒｓ）およびその使用方法
CA3033079A1 (en) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
CA3035528A1 (en) 2016-08-31 2018-03-08 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
AU2017328910B2 (en) 2016-09-19 2020-04-09 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
ES2968453T3 (es) 2016-09-19 2024-05-09 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato
JP6781832B2 (ja) 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
CN113288869A (zh) 2016-09-19 2021-08-24 墨西哥氟石股份公司 药物组合物
CA3037961A1 (en) 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
CA3037746A1 (en) 2016-10-07 2018-04-12 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
EP3538100A2 (de) 2016-11-14 2019-09-18 CeMM - Forschungszentrum für Molekulare Medizin GmbH Kombination aus einem brd4-inhibitor und einem antifolat zur behandlung von krebs
JP2020502261A (ja) 2016-11-16 2020-01-23 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬を治療する方法
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
EP3621616A4 (de) 2017-05-10 2021-01-13 InCarda Therapeutics, Inc. Einheitsdosen, aerosole, kits und verfahren zur behandlung von herzleiden mittels pulmonaler verabreichung
JP7210476B2 (ja) 2017-05-22 2023-01-23 インスメッド インコーポレイテッド リポ‐グリコペプチド可切断性誘導体及びその使用
JP7202376B2 (ja) 2017-07-20 2023-01-11 エーゼットセラピーズ， インコーポレイテッド クロモリンナトリウムおよびイブプロフェンの粉末製剤
JP2020532987A (ja) 2017-09-08 2020-11-19 ポセイダ セラピューティクス，インコーポレイティド キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
US20210179591A1 (en) 2017-12-05 2021-06-17 Eth Zurich New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
MX2020006689A (es) 2017-12-20 2020-11-06 Poseida Therapeutics Inc Composiciones de vcar y metodos de uso.
CA3092551A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
BR112020018049A2 (pt) 2018-03-07 2020-12-29 Poseida Therapeutics, Inc. Composições de cartirina e métodos para uso
WO2019183470A2 (en) 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
AU2019247641A1 (en) 2018-04-06 2020-11-12 Zilentin AG Bumetanide derivatives for the therapy of hyperhidrosis
WO2019193161A1 (en) 2018-04-06 2019-10-10 Universität Wien Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs
JP2021523138A (ja) 2018-05-11 2021-09-02 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ−２３抗体を使用してうつを治療する方法
US10414721B1 (en) 2018-06-04 2019-09-17 University Of Bern Inhibitor of endocannabinoid cellular reuptake
WO2020010049A1 (en) 2018-07-02 2020-01-09 The General Hospital Corporation POWDERED FORMULATIONS OF CROMOLYN SODIUM AND α-LACTOSE
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
DK3883606T5 (da) 2018-09-24 2024-01-02 Janssen Biotech Inc Sikker og effektiv fremgangsmåde til behandling af colitis ulcerosa med anti-il12/il23-antistof
KR20210093973A (ko) 2018-11-20 2021-07-28 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
WO2020127200A1 (en) 2018-12-17 2020-06-25 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
WO2020128864A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
US11390571B2 (en) 2019-01-03 2022-07-19 Aqua Yield Operations LLC PAMAM dendrimers for fertilizer delivery
EP3938384A4 (de) 2019-03-14 2022-12-28 Janssen Biotech, Inc. Herstellungsverfahren zur herstellung von anti-il12/il23-antikörperzusammensetzungen
BR112021018441A2 (pt) 2019-03-18 2023-02-28 Janssen Biotech Inc Método para tratamento de psoríase em indivíduos pediátricos com anticorpo anti-il12/il23
US11932585B2 (en) 2019-04-12 2024-03-19 Aqua Yield Operations LLC Blended nanoparticle fertilizer delivery
CN110051868A (zh) * 2019-04-15 2019-07-26 宝盈联华(厦门)生物科技有限公司 一种带有硅碳岩、礌石粉的橱柜灭菌器
JP7404671B2 (ja) * 2019-06-25 2023-12-26 株式会社リコー 多孔質微粒子及びその製造方法、並びに医薬組成物
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
WO2021064141A1 (en) 2019-10-02 2021-04-08 Tolremo Therapeutics Ag Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
EP4041399A1 (de) 2019-10-02 2022-08-17 Tolremo Therapeutics AG Heterocyclische derivate, pharmazeutische zusammensetzungen und deren verwendung zur behandlung oder linderung von krebs
EP4045142A1 (de) 2019-10-16 2022-08-24 CeMM - Forschungszentrum für Molekulare Medizin GmbH Oxazol- und thioazin-ring-ubiquitin-ligase-verbindungen und verwendungen davon
WO2021074418A1 (en) 2019-10-16 2021-04-22 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
KR20230011295A (ko) 2020-04-14 2023-01-20 포세이다 테라퓨틱스, 인크. 암 치료에 사용하기 위한 조성물 및 방법
US20230158125A1 (en) 2020-04-20 2023-05-25 Sorrento Therapeutics, Inc. Pulmonary Administration of ACE2 Polypeptides
WO2021214588A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating coronavirus infections
WO2021214587A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating viral infections
US20230226057A1 (en) 2020-06-25 2023-07-20 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
EP3939578A1 (de) 2020-07-13 2022-01-19 Novaremed Ltd. Verbindungen zur behandlung oder vorbeugung einer infektion, die aus einer coronavirus- und/oder einer coronavirusinduzierten erkrankung resultiert
CN111700883B (zh) * 2020-07-23 2021-04-06 深圳大佛药业股份有限公司 一种硫酸沙丁胺醇缓释型吸入制剂及其生产工艺
EP4208154A1 (de) 2020-09-04 2023-07-12 Mexichem Fluor S.A. de C.V. Pharmazeutische zusammensetzung
EP3964497A1 (de) 2020-09-04 2022-03-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Substituierte vicinale diaminverbindungen und deren verwendung zur behandlung, linderung oder vorbeugung von schmerzen
JP2023545588A (ja) 2020-10-16 2023-10-30 ツェーエムエム－フォルシュングスツェントルム フュア モレクラレ メディツィン ゲーエムベーハー ヘテロ環式カリンｒｉｎｇユビキチンリガーゼ化合物及びその使用
CN112495316B (zh) * 2020-10-20 2021-11-19 大连理工大学 一种基于亚稳态乳液制备微纳米凝胶微球的方法
WO2022122012A1 (zh) * 2020-12-11 2022-06-16 江苏恒瑞医药股份有限公司 用于肺部递送的药物组合物
WO2022189662A1 (en) 2021-03-12 2022-09-15 Alvarius Pharmaceuticals Ltd. Compositions and methods for treating addictions comprising 5-meo-dmt
EP4305062A1 (de) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Verfahren zur behandlung von patienten mit psoriasisarthritis mit unzureichender reaktion auf eine tnf-therapie mit anti-il23-spezifischem antikörper
US20220298236A1 (en) 2021-03-12 2022-09-22 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
KR20230167092A (ko) 2021-04-07 2023-12-07 톨레모 테라퓨틱스 아게 헤테로사이클릭 유도체, 약학 조성물, 및 암의 치료 또는 개선에서의 그들의 용도
CN117916260A (zh) 2021-07-09 2024-04-19 詹森生物科技公司 用于制备抗il12/il23抗体组合物的制造方法
KR20240099352A (ko) 2021-10-29 2024-06-28 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
AU2022388887A1 (en) 2021-11-15 2024-07-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2023187707A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
WO2023203172A1 (en) 2022-04-20 2023-10-26 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
CN115144310A (zh) * 2022-07-01 2022-10-04 重庆交通大学 一种旋桨式絮凝沉降试验装置及方法
WO2024110898A1 (en) 2022-11-22 2024-05-30 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1410588A (en) † 1971-08-10 1975-10-22 Fisons Ltd Composition
JPS5134879A (en) * 1974-09-19 1976-03-24 Eisai Co Ltd Bishochukuryushinoseizoho
US4147766A (en) † 1976-06-09 1979-04-03 Armour Pharmaceutical Company Macrospherical particles of anti-perspirants
DE3268533D1 (en) * 1981-07-24 1986-02-27 Fisons Plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
JP2867404B2 (ja) * 1983-11-14 1999-03-08 ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション ドラッグデリバリーのための多孔性ミクロスフェアおよびその製造法
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
GB8502892D0 (en) * 1985-02-05 1985-03-06 Sterwin Ag Aerosol composition
ATE78158T1 (de) * 1985-05-22 1992-08-15 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
US4950477A (en) † 1988-08-23 1990-08-21 Memorial Hospital For Cancer And Allied Dieseas Method of preventing and treating pulmonary infection by fungi using aerosolized polyenes
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
DE69005800T2 (de) * 1989-05-01 1994-05-19 Alkermes Inc Verfahren zur herstellung von kleinen partikeln von biologisch aktiven molekülen.
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
AU7908791A (en) † 1990-05-08 1991-11-27 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
US5126123A (en) † 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
US5230884A (en) † 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5304125A (en) † 1990-10-05 1994-04-19 The University Of North Carolina Apparatus for administering solid particulate aerosols to the lungs
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
ATE147976T1 (de) * 1991-01-15 1997-02-15 Hemosphere Inc Protein nanomatrizen und verfahren zur herstellung
US5182097A (en) † 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
CA2082951C (en) † 1991-03-15 1999-12-21 Robert M. Platz Pulmonary administration of granulocyte colony stimulating factor
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
JPH05500229A (ja) * 1991-04-12 1993-01-21 東レ株式会社 固体ポリペプチド微粒子のエアロゾル製剤とその製造方法
EP0588897B1 (de) * 1991-06-10 1996-02-28 Schering Corporation Fluorchlorkohlenwasserstoffreie aerosolformulierungen
EP0717987B1 (de) * 1991-12-18 2001-08-29 Minnesota Mining And Manufacturing Company Aerosolzusammensetzungen für Arzneimittelsuspensionen
US5376359A (en) † 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5354934A (en) † 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
US5798091A (en) † 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
WO1995003835A1 (en) * 1993-07-30 1995-02-09 Alliance Pharmaceutical Corp. Stabilized microbubble compositions for ultrasound
EP0655237A1 (de) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
BR9509171A (pt) * 1994-09-29 1997-09-16 Andaris Ltd Microparticulas secas por borrifamento como veículos terapêuticos
GB9423419D0 (en) * 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
MY131733A (en) * 1994-12-22 2007-08-30 Astra Ab Aerosol drug formulations
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
KR19980703876A (ko) * 1995-04-14 1998-12-05 스티븐 엘. 허스트 분산성이 개선된 분말화된 약학적 조성물
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
JP4215820B2 (ja) † 1995-06-07 2009-01-28 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 診断的および治療的使用のための新規な標的化組成物
US6041777A (en) * 1995-12-01 2000-03-28 Alliance Pharmaceutical Corp. Methods and apparatus for closed-circuit ventilation therapy
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
ATE287257T1 (de) † 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
DE69814428T2 (de) * 1997-09-29 2004-05-13 Nektar Therapeutics, San Carlos In verneblern verwendbare, stabilisierte zubereitungen

Also Published As

Publication number Publication date
EP1019022B1 (de) 2003-04-23
AU1185799A (en) 1999-04-23
DE69813853T3 (de) 2011-05-12
HRP20000175A2 (en) 2001-06-30
KR100575070B1 (ko) 2006-05-03
DK1019022T3 (da) 2003-07-28
CA2304819A1 (en) 1999-04-08
JP4526702B2 (ja) 2010-08-18
DE69813853T2 (de) 2004-01-29
NO20001618D0 (no) 2000-03-28
PT1019022E (pt) 2003-08-29
DK1019021T3 (da) 2003-11-10
SK4492000A3 (en) 2000-09-12
HK1031680A1 (en) 2001-06-22
CZ20001115A3 (cs) 2000-09-13
AU757153B2 (en) 2003-02-06
NO340149B1 (no) 2017-03-13
WO1999016422A1 (en) 1999-04-08
WO1999016419A1 (en) 1999-04-08
CA2304973C (en) 2009-11-17
EE04628B1 (et) 2006-06-15
CA2304820C (en) 2009-06-23
IL135126A0 (en) 2001-05-20
EP1019020A1 (de) 2000-07-19
CZ300758B6 (cs) 2009-08-05
MEP4108A (xx) 2010-02-10
BG104253A (en) 2000-11-30
KR100589926B1 (ko) 2006-06-15
AU9677098A (en) 1999-04-23
DE69813853D1 (de) 2003-05-28
DK1019021T4 (da) 2013-01-07
HRP20000175B1 (en) 2004-06-30
ES2205560T3 (es) 2004-05-01
KR20010030810A (ko) 2001-04-16
ATE238035T1 (de) 2003-05-15
CN1169520C (zh) 2004-10-06
TR200000819T2 (tr) 2001-06-21
CA2304975C (en) 2009-06-16
JP6100114B2 (ja) 2017-03-22
AU9677298A (en) 1999-04-23
JP6078498B2 (ja) 2017-02-08
EA200200036A1 (ru) 2002-04-25
EA003665B1 (ru) 2003-08-28
DE69814428D1 (de) 2003-06-12
NO20001618L (no) 2000-05-19
JP5739197B2 (ja) 2015-06-24
AU1064499A (en) 1999-04-23
JP2001517691A (ja) 2001-10-09
CA2304973A1 (en) 1999-04-08
AU750567B2 (en) 2002-07-25
DE69814428T2 (de) 2004-05-13
JP2011116788A (ja) 2011-06-16
RS50182B (sr) 2009-05-06
AU757337C (en) 2005-11-03
EP1019021A1 (de) 2000-07-19
NZ503464A (en) 2002-05-31
JP2013216688A (ja) 2013-10-24
AU756693B2 (en) 2003-01-23
JP2003525842A (ja) 2003-09-02
KR20010030788A (ko) 2001-04-16
EP1019023A1 (de) 2000-07-19
WO1999016421A1 (en) 1999-04-08
IS5415A (is) 2000-03-24
JP2014169335A (ja) 2014-09-18
CA2304820A1 (en) 1999-04-08
IL135126A (en) 2006-04-10
ES2195408T5 (es) 2010-11-25
EP1019021B1 (de) 2003-09-03
CA2304819C (en) 2008-04-08
JP2003525841A (ja) 2003-09-02
EP1019022B2 (de) 2010-07-28
BR9812693A (pt) 2000-08-22
EA002562B1 (ru) 2002-06-27
KR100572171B1 (ko) 2006-04-19
EP1019023B1 (de) 2003-05-07
EP1019021B2 (de) 2012-12-26
CA2304975A1 (en) 1999-04-08
CN1272058A (zh) 2000-11-01
IS2154B (is) 2006-10-13
JP2001517692A (ja) 2001-10-09
PL339732A1 (en) 2001-01-02
PL195212B1 (pl) 2007-08-31
WO1999016419A9 (en) 1999-08-19
JP5372306B2 (ja) 2013-12-18
ATE239447T1 (de) 2003-05-15
ES2195415T3 (es) 2003-12-01
EE200000194A (et) 2001-04-16
ES2205560T5 (es) 2013-04-16
JP2010047615A (ja) 2010-03-04
AU757337B2 (en) 2003-02-20
ES2195408T3 (es) 2003-12-01
JP2013199497A (ja) 2013-10-03
KR20010030787A (ko) 2001-04-16
KR20010030801A (ko) 2001-04-16
BG64816B1 (bg) 2006-05-31
DK1019022T4 (da) 2010-11-08
KR100599634B1 (ko) 2006-07-12
YU18300A (sh) 2003-02-28
SK285068B6 (sk) 2006-05-04
EP1019022A1 (de) 2000-07-19
EA200000375A1 (ru) 2000-12-25

Similar Documents

Publication Publication Date Title
ATE248583T1 (de) In dosierinhalatoren verwendbare, stabilisierte zubereitungen
PT904056E (pt) Processo e dispositivo para inalacao de medicamentos particulados
HUP0102468A2 (hu) Nyomás alatti dózisadagoló inhaláló berendezés és aeroszol formájú gyógyászati készítmények
SE9700423D0 (sv) Disposable inhaler
MXPA02008403A (es) Mejoras en o relacionadas con el suministro de farmacos por via oral.
JO2381B1 (en) Formulation containing anticholinergic drug for the treatment of chronic obstructive pulmonary disease
EE03221B1 (et) Inhaleeritavad ravimpreparaadid, nende valmistamise protsess ja inhalaator nende kasutamiseks
WO2002024158A3 (en) Pulmonary delivery in treating disorders of the central nervous system
KR930701992A (ko) 환자의 폐에 잔존하는 점액 분비물의 제거 방법
DE60008425D1 (de) Medikamentenabgabevorrichtung mit einer feuchtigkeitsbeständigen beschichtung
ATE271852T1 (de) Verbesserte inhalationspräparate
EP1110547A3 (de) Helium und Neon als Hilfsstoffe zur Wirkstoffverabreichung mittels Inhalator
TH33149A (th) สูตรผสมละอองลอยที่เป็นยา

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties